Relay Therapeutics, Inc. (RLAY)
NASDAQ: RLAY · Real-Time Price · USD
9.15
+0.16 (1.78%)
At close: Feb 11, 2026, 4:00 PM EST
8.97
-0.18 (-1.97%)
After-hours: Feb 11, 2026, 6:27 PM EST
Relay Therapeutics Employees
Relay Therapeutics had 188 employees as of September 30, 2025. The number of employees decreased by 106 or -36.05% compared to the same quarter last year.
Employees
188
Change
-106
Growth
-36.05%
Revenue / Employee
$44,441
Profits / Employee
-$1,582,941
Market Cap
1.59B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Sep 30, 2025 | 188 | -106 | -36.05% |
| Jun 30, 2025 | 197 | -107 | -35.20% |
| Mar 31, 2025 | 259 | -50 | -16.18% |
| Dec 31, 2024 | 261 | -62 | -19.20% |
| Sep 30, 2024 | 294 | -49 | -14.29% |
| Jun 30, 2024 | 304 | -41 | -11.88% |
| Mar 31, 2024 | 309 | -19 | -5.79% |
| Dec 31, 2023 | 323 | -4 | -1.22% |
| Sep 30, 2023 | 343 | 23 | 7.19% |
| Jun 30, 2023 | 345 | 40 | 13.11% |
| Mar 31, 2023 | 328 | 52 | 18.84% |
| Dec 31, 2022 | 327 | 82 | 33.47% |
| Sep 30, 2022 | 320 | 88 | 37.93% |
| Jun 30, 2022 | 305 | 102 | 50.25% |
| Mar 31, 2022 | 276 | 113 | 69.33% |
| Dec 31, 2021 | 245 | 86 | 54.09% |
| Sep 30, 2021 | 232 | 100 | 75.76% |
| Jun 30, 2021 | 203 | 80 | 65.04% |
| Mar 31, 2021 | 163 | 41 | 33.61% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Agios Pharmaceuticals | 488 |
| Biohaven | 256 |
| Celldex Therapeutics | 186 |
| AnaptysBio | 136 |
| Tyra Biosciences | 60 |
| Oculis Holding AG | 49 |
| Sionna Therapeutics | 48 |
| MBX Biosciences | 43 |
RLAY News
- 7 days ago - Relay Therapeutics to Participate in Guggenheim Emerging Outlook: Biotech Summit 2026 - GlobeNewsWire
- 8 days ago - Relay Therapeutics Announces Zovegalisib Granted Breakthrough Therapy Designation by U.S. FDA for PIK3CA-mutant, HR+/HER2- Advanced Breast Cancer - GlobeNewsWire
- 14 days ago - Oppenheimer Upgrade Fuels Relay Therapeutics Rally On Zovegalisib Optimism - Seeking Alpha
- 2 months ago - Relay Therapeutics Announces Efficacy Subset Analysis of Zovegalisib (RLY-2608) + Fulvestrant in Breast Cancer Patients Pre-Treated with SERD or with ESR1 Mutations at SABCS 2025 - GlobeNewsWire
- 2 months ago - Relay Therapeutics, Inc. (RLAY) Presents at Jefferies London Healthcare Conference 2025 Transcript - Seeking Alpha
- 3 months ago - Relay Therapeutics Reports Third Quarter 2025 Financial Results and Corporate Updates - GlobeNewsWire
- 3 months ago - Relay Therapeutics to Participate in Two Upcoming Investor Conferences in November - GlobeNewsWire
- 3 months ago - Relay Therapeutics to Announce Third Quarter 2025 Financial Results and Corporate Highlights on November 6, 2025 - GlobeNewsWire